Skip to main content
Skip to Investors Navigation
About
Company
Management Team
Corporate Governance
Technology
Pb-based α-Particle Therapy
Precision Radiopharmaceuticals
Pb-Specific Chelator (PSC)
Theranostics Platform
Manufacturing/Logistics
Therapeutic Areas
Neuroendocrine Tumors
Melanoma
Solid Tumors
Pipeline
Program Overview
VMT-α-NET
VMT01/02
PSV359
Pre-Targeting Platform
Expanded Access
Newsroom
News
Press Releases
Publications
Investor Center
Overview
Events
SEC Filings
Stock Data
Corporate Governance
Contact Info
Alerts
Newsroom
News
Media Coverage